Tocagen
4242 Campus Point Court
Suite 500
San Diego
California
92121
United States
This animation demonstrates the proposed mechanism of action for Tocagen’s lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC, and is based primarily on preclinical data.
Toca 511 & Toca FC is an investigational therapy, which has not been proven to be safe or effective for any use and is not approved by the U.S. Food and Drug Administration or any other government agency.
Tocagen is developing broadly applicable, cancer-selective immunotherapy treatments for cancer, including high grade glioma, a type of brain cancer. The company’s lead product combines Toca 511 with Toca FC. The therapeutic regimen involves two discrete steps with Toca 511 given first followed by treatment with Toca FC.
109 articles about Tocagen
-
Tocagen Announces Change to Virtual Format for Special Meeting of Stockholders
5/28/2020
Tocagen Inc. announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, it is changing its special meeting of stockholders related to its previously announced proposed merger with Forte Biosciences, Inc. to a virtual-only format that will be held via live audio webcast.
-
As Tocagen heads into its reverse merger with Forte Biosciences, Denovo Biopharma swooped in to snap up that company’s retroviral replicating vector platform (RRV), including an asset that stumbled in a Phase III study that Denovo believes still has some life.
-
Tocagen Reports First Quarter 2020 Financial Results
4/23/2020
Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020.
-
Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results
2/27/2020
Definitive merger agreement with Forte Biosciences announced February 19, 2020
-
The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis.
-
Tocagen and Forte Biosciences Announce Merger
2/20/2020
Transaction to Create Nasdaq-listed Company Focused on Advancing Forte's Late-Stage Clinical Program for Atopic Dermatitis
-
These are the top biotech companies headquartered in Biotech Beach based on 2018 revenue. Here’s the brief information including the revenue of each company.
-
Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting
11/22/2019
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) at the Society for Neuro-Oncology (SNO) Annual Meeting.
-
Tocagen Reports Third Quarter 2019 Financial Results and Business Updates
11/12/2019
On September 12, Tocagen announced the pivotal Toca 5 Phase 3 clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) missed the primary endpoint of overall survival compared to standard of care treatment and all secondary endpoints.
-
Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting
11/8/2019
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Company presented data from the Toca 6 Phase 1b study of Toca 511 and Toca FC in patients with non-CNS tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, MD and will have two presentations related to brain cancer at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO), to be held Nov. 20-24 in Phoenix.
-
Tocagen to Report Third Quarter 2019 Financial Results and Business Updates on Tuesday, November 12
11/6/2019
Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, announced it will report its third quarter 2019 financial results and business progress on Tuesday, November 12, 2019, after the close of the U.S. financial markets.
-
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
-
Less than a month after its Phase III brain cancer treatment failed, San Diego-based Tocagen is undergoing a company restructuring and will reduce its workforce by approximately 65%, the company announced late Thursday.
-
Tocagen Announces Restructuring to Focus on Clinical Development
10/3/2019
Toca 5 full results to be presented at the upcoming Society for Neuro-Oncology Annual Meeting
-
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
9/12/2019
Tocagen Inc. announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma undergoing resection missed the primary endpoint of overall survival compared to standard of care treatment.
-
Tocagen said the late-stage Toca 5 trial evaluating Toca 511 & Toca FC in patients with recurrent high-grade glioma undergoing resection missed its overall survival endpoint compared to standard of care treatment.
-
Tocagen to Participate in Two Upcoming Investor Conferences
8/26/2019
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced Marty Duvall, chief executive officer, will present and webcast at the Baird 2019 Global Healthcare Conference in New York on Wednesday, September 4 at 2:30 PM Eastern.
-
Tocagen Reports Second Quarter 2019 Financial Results and Business Updates
8/8/2019
Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, reported financial results and business highlights for the second quarter ended June 30, 2019.
-
Tocagen to Report Second Quarter 2019 Financial Results and Business Updates on Thursday, August 8
8/1/2019
Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its second quarter 2019 financial results and business progress on Thursday, August 8, 2019, after the close of the U.S. financial markets.
-
Tocagen to Present at Upcoming Jefferies 2019 Healthcare Conference
5/30/2019
Tocagen Inc. announced Marty Duvall, chief executive officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, at 4:00 p.m. ET in New York City.